CTEP must review and approve all protocols involving CTEP ...
[pic]
Green – for items getting ‘Full Review’
Yellow – for item getting ‘Safety Review’
Blue – for item getting ‘Developmental Strategy Review’
Red – for item not reviewed by CTEP
CTEP’s Protocol Review Committee (which includes staff of other DCTD programs, plus ad hoc reviewers) must review the following categories of protocols*
• studies involving CTEP supplied investigational agents
• all CTEP funded Cooperative Group and Consortium (NABTT, NABTC, PBTC, AMC, etc.) trials
• CCOP research base treatment
• ACRIN protocols that involve treatment interventions
The type of review is dependent on whether the study:
• utilizes a CTEP IND agent;
• is from a CTEP funded trial organization and which type (e.g., Cooperative Groups vs. UO1 funded Consortia);
• has already received NIH-type peer review for the specific protocol (e.g. R21)
• focus is on treatment vs. correlative science;
• involves collaboration in an ongoing international trial;
• is expected to accrue > 100 patients;
• is a phase 1, 2 or 3 trial.
A summary of the review types follows:
• Full Review –
o Types of studies: All studies that utilize a CTEP IND agent and are not specifically peer reviewed; OR CTEP funded treatment trials with an expected accrual > 100 patients; OR all consortia trials funded by a cooperative agreement or contract.
o Focus of NCI review: The protocol is reviewed for completeness and clarity; scientific merit risk: benefit ratio; optimal design; accrual rate; patient safety; pharmaceutical accuracy; adequacy of regulatory and human subject’s protection aspects; and agent availability and duplication with existing studies.
o NCI Reviewer comments: Reviewers may provide ‘comments requiring a response’ and/or ‘recommendations’ to modify any aspect of the trial.
o Typical assignment of NCI reviewers: IDB; BRB; PMB; CTMB; CIB (if disease specific, phase 2 or 3; or Group involvement); and other specialists as appropriate (e.g. imaging; bio-markers; quality-of-life; etc..).
• Safety Review –
o Types of trials: Group phase 1 treatment trial without a CTEP IND agent AND an expected accrual < 100 patients; OR the study has received funding after specific NIH-type peer review.
o Focus of NCI review: The protocol is reviewed for patient safety; pharmaceutical accuracy; and adequacy of regulatory and human subject’s protection aspects.
o NCI Reviewer comments: Reviewers may provide ‘recommendations’ and/or ‘comments requiring a response’ to modify the study within the focus area of the review. Recommendation maybe made in other areas for CTEP IND agent studies.
o Typical assignment of NCI reviewers: CIB; CTMB; & PMB (if a treatment trial). Other reviewers with specialized expertise may be assigned as appropriate.
• International Collaboration –
o Types of Trials:: When CTEP-funded organizations, typically Cooperative Groups, wish to join a new trial or a study already under way under the sponsorship of another major international clinical trials organization (e.g. EORTC).
o Focus of NCI review: It is assumed that as a result of the prior international review, that there would be limited ability to reconsider major design issues. In this case the protocol is reviewed first with regard to whether the scientific question merits commitment of funded CTEP resources, and if so it is reviewed for patient safety; pharmaceutical accuracy; and adequacy of regulatory and human subject’s protection aspects.
o NCI Reviewer comments: Will focus on whether to commit Group resources towards the trial. Other comments will be limited to recommendations within the focus area of the review.
o Typical assignment of NCI reviewers: CIB; PMB; BRB & CTMB. Other reviewers with specialized expertise may be assigned as appropriate.
• Developmental Strategy Review –
o Types of Trials: These are Cooperative Group phase 2 treatment trials without a CTEP IND agent AND an expected accrual < 100 patients that are undertaken as preliminary to an eventual large randomized phase 3 trial (with its attendant commitment of substantial resources and funds); or a definitive correlative science (non-treatment) trial with expected accrual of > 100 patients..
o Focus of NCI review: Review at this stage provides the Group with an early indication of the potential scientific value of an eventual phase 3 question. Particularly in the context of other potential trials.
o NCI reviewer Comments: This category of protocol receives a limited review. In general NCI comments will be limited to “recommendations only” regarding the scientific merit of the protocol. These studies are not reviewed by NCI for human subject protection or for pharmaceutical and regulatory accuracy/compliance. The submitting organization assumes full responsibility for assuring compliance with all federal or NCI-specific regulations regarding these regulatory and safety issues for this category of trials. In the event that a NCI scientific reviewer finds a regulatory or safety issue that is incorrect or non-compliant in the course of this limited review, this will be indicated to the Group as “comments requiring a response”.
o Typical assignment of NCI reviewers: CIB and BRB (and CDP for non-treatment trials)
• File Only –
o Types of Trials: All non-treatment trials with expected accrual < 100
o Focus of NCI review: No review required.
o NCI reviewer comments: None provided. The submitting organization assumes full responsibility for assuring compliance with all federal or NCI-specific regulations regarding these regulatory and safety issues for any file-only study.
o Typical assignment of NCI reviewers: None required.
Please note: Trials without NIH funding, trials with commercial agent or industry sponsored IND’s, without CTEP IND agents, (e.g. SPORE or cancer center trials using industry or locally supplied agents) do not get any CTEP review. The investigator & institution are entirely responsible for compliance with federal and local regulations.
-----------------------
YES
YES
YES
CTEP REVIEW TYPES DIAGRAM
Treatment /
Ancillary Studies
CTEP Funded
Consortium or
International
Collaboration
NIH Type
Peer Review
of Protocol
(Examples:
Industry sponsored
Cancer Center Trials, investigator Initiated, charitable-funded trials, Trials with investigator
IND’s, etc..)
Safety
Review
NO
R21 type
detailed Peer
Review of
Protocol
Developmental
Strategy
File Only
No
Treatment
Phase 2
NO CTEP FUNDING
NO
Safety
Review
Phase 1
< 100
> 100
Full Review
No
Submission
Required
Expected
Accrual
Cooperative
Group
CTEP IND
CTEP FUNDING
NO CTEP IND
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- record review tool for providers texas health and human
- tqr ready review comments nsuworks
- ctep must review and approve all protocols involving ctep
- employee probationary performance review
- missouri reviewer comments pdg 2014 ms word
- feedback to students on their work and progress
- periodic evaluation vs performance review
- individual performance plan and evaluation the
- djjdp monitoring review report north carolina
- literature review outline
Related searches
- colonial penn review and ratings
- review and practice protein synthesis
- 100 must read books of all time
- s and p all time high
- lincoln financial group review and ratings
- light headed and tired all the time
- pain in joints and muscles all over
- performance review and goals answers
- numbness and tingling all over body
- tired and sore all over
- tired and weak all the time
- copy and paste all emojis